Stallion Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Stallion Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $7.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Stallion Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $7.7M Trade | TransData Nexus

Stallion Laboratories Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $7.7M Total Trade · DGFT Verified

Stallion Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $7.7M across 6 products in 5 therapeutic categories. Based on 362 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Amino ($3.3M), Gliclazide ($2.7M), Piperacillin ($755.1K).

Stallion Laboratories Private Limited — Export Portfolio & Destination Treemap

Stallion Laboratories Private Limited pharmaceutical export portfolio — 6 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Stallion Laboratories Private Limited? — Company Overview & Market Position

Stallion Laboratories Private Limited, established on January 18, 1988, is a privately held pharmaceutical formulation manufacturer headquartered in Ahmedabad, Gujarat, India. The company operates under the Corporate Identification Number (CIN) U24231GJ1988PTC010285 and is registered with the Registrar of Companies, Ahmedabad. As of the latest available data, Stallion Laboratories has an authorized capital of ₹10.00 crore and a paid-up capital of ₹2.53 crore.

The company employs over 400 qualified staff members and has a diverse product portfolio, exporting to more than 70 countries. Stallion Laboratories specializes in the manufacturing of tablets, capsules, liquids, and powders, catering to both emerging markets and the U.S. market.

What Does Stallion Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amino$3.3M 2Gliclazide$2.7M

Product Portfolio — Top 6 by Export Value

Stallion Laboratories Private Limited exports 6 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amino	Nutritional Supplements	$3.3M	65	1.0%	15
2	Gliclazide	Advanced Diabetes Medications	$2.7M	115	0.9%	9
3	Piperacillin	Advanced Antibiotics	$755.1K	87	0.9%	11
4	Febuxostat	Lipid & Metabolism	$478.4K	70	1.0%	11
5	Lisinopril	Cardiovascular	$300.0K	6	0.5%	6
6	Captopril	Cardiovascular	$189.4K	19	1.5%	6

Stallion Laboratories Private Limited exports 6 pharmaceutical products across 5 therapeutic categories with a total export value of $7.7M. The top category is Nutritional Supplements (42.3% of portfolio), followed by Advanced Diabetes Medications (35.3%), indicating a concentrated portfolio with the top 5 products accounting for 97.5% of total export value.

Stallion Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Stallion Laboratories operates two manufacturing facilities:

1. Unit 1: Designed for emerging markets, this facility produces a wide range of pharmaceutical formulations, including tablets, capsules, liquids, and powders.

2. Unit 2: Tailored for the U.S. market, this unit focuses on the production of general tablets and capsules.

Both units adhere to stringent quality control measures and are equipped with modern technology to ensure compliance with international standards.

3Key Leadership

The leadership team at Stallion Laboratories includes:

Arvindkumar Jayantilal Thakker: Director

Vijay Jasvantlal Shah: Director

Vipulkumar Rajnikant Shah: Director

These individuals have been instrumental in steering the company towards its current position in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Stallion Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Stallion Laboratories has made significant strides in regulated markets:

United States: The company has FDA registrations for its facilities and has filed Abbreviated New Drug Applications (ANDAs) for various products. (fda.report)

European Union and United Kingdom: While specific regulatory approvals are not detailed, Stallion Laboratories exports to Europe and the UK, indicating compliance with EU and UK regulations.

Australia and Japan: The company's export activities in these regions suggest adherence to respective regulatory standards, though specific approvals are not specified.

2Emerging Markets

Stallion Laboratories has a strong presence in emerging markets:

Africa, Latin America, and Southeast Asia: The company exports to over 70 countries, including regions in Africa, Latin America, and Southeast Asia, indicating a broad market reach.

Stallion Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Stallion Laboratories' FDA status includes:

Facility Registrations: The company has FDA-registered facilities for the manufacture of pharmaceutical products. (fda.report)

Approved ANDAs: Specific details on approved Abbreviated New Drug Applications (ANDAs) are not provided.

DMF Filings: Information regarding Drug Master File (DMF) filings is not available.

Inspection History: The company has undergone FDA inspections, with the most recent Form 483 issued on March 24, 2023.

2WHO & EU GMP

Stallion Laboratories holds certifications that reflect its commitment to quality:

Stallion Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical formulation sector, Stallion Laboratories faces competition from:

Top Competitors: Companies such as Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's Laboratories operate in overlapping therapeutic categories.

Market Share Comparison: Stallion Laboratories holds a 1.0% market share in amino formulations, 0.9% in gliclazide and piperacillin, and 0.5% in lisinopril, indicating a niche presence.

Head-to-Head Analysis: While larger competitors dominate the market, Stallion Laboratories' focus on niche products allows for specialized market positioning.

2Key Differentiators

Stallion Laboratories' unique strengths include:

Product Portfolio: A diverse range of products across multiple therapeutic categories, with a significant focus on nutritional supplements and advanced diabetes medications.

Buyer Due Diligence Brief — Evaluating Stallion Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

As a supplier, Stallion Laboratories demonstrates:

Track Record: Over 35 years in the pharmaceutical manufacturing industry, with a consistent export volume of $7.7 million USD across 362 shipments.

Export Consistency: Regular exports to more than 70 countries, indicating reliability and market acceptance.

Reliability Indicators: Compliance with international quality standards and regulatory approvals, though recent FDA observations suggest areas for improvement.

2Certifications to Verify

Importers should verify the following certifications:

FDA Registration: Confirm the company's FDA registration status for facility and product approvals.

Frequently Asked Questions — Stallion Laboratories Private Limited

How many pharmaceutical products does Stallion Laboratories Private Limited export from India?

Stallion Laboratories Private Limited exports 6 pharmaceutical products across 5 therapeutic categories. The top exports are Amino ($3.3M), Gliclazide ($2.7M), Piperacillin ($755.1K), Febuxostat ($478.4K), Lisinopril ($300.0K). Total export value is $7.7M.

What is Stallion Laboratories Private Limited's total pharmaceutical export value?

Stallion Laboratories Private Limited's total pharmaceutical export value is $7.7M, based on 362 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Stallion Laboratories Private Limited cover?

Stallion Laboratories Private Limited exports across 5 therapeutic categories. The largest are Nutritional Supplements (42.3%, 1 products), Advanced Diabetes Medications (35.3%, 1 products), Advanced Antibiotics (9.8%, 1 products).

Get Full Stallion Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.